Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Next Previous
X
Search
Trial Profile

A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirasemtiv (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms VITALITY-ALS
  • Sponsors Cytokinetics

    • Most Recent Events

    • 01 Feb 2025 Results of an analysis assessing meaningful correlations in plasma Nf concentrations at baseline by demographics or clinical features, and the relationship of Nf baseline concentrations and change in Nf concentrations over 48 weeks using clinical data from this trial published in the Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
    • 29 Nov 2023 According to Cytokinetics media release, data from this study will be presented at the 34th International Symposium
    • 04 Aug 2022 According to a Cytokinetics media release, the company announced the release of pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top